- FibroGen ( NASDAQ: FGEN ) said on Friday it had completed patient enrollment for Phase 3 clinical study of roxadustat for treatment of anemia in patients with lower risk transfusion-dependent myelodysplastic syndromes.
- A total of 141 subjects have been enrolled in the late-stage double-blind placebo-controlled study investigating the efficacy and safety of the drug.
- The primary endpoint of the study is transfusion independence for ? 56 consecutive days in the first 28 weeks of treatment.
- Data from the study is expected in 1H 2023.
For further details see:
FibroGen completes patient enrollment for Roxadustat to treat anemia in patients